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Chronicfoot ulcers are common in long-standing diabetes, may herald severe complications and
are often resistant to therapy. To evaluate the effects ofadjunctive topical hyperbaric oxygen treat-
ment (THBO) and low energy laser (LEL) irradiation on ulcer healing, a 100 consecutive patients
with chronic diabeticfoot ulcers (DFU) refractory to 4.5 ± 1.2 months ofcomprehensive treatment,
were enrolled in a prospective open study. While conventional treatment was continued as neces-
sary, THBO was administered bypumping 100percent oxygen into a disposable sealedpolythylene
hyperbaric chamber (150 min x 2 to 3/wk at up to 1.04 atm). Helium-neon LEL irradiation was
given concurrently using a Unilaser Scan Unitat4J/cm2for20min. Somepatients continued THBO
athome ortheirtreatment was confined to THBO athome. Patients were monitoredevery two weeks
revealing 81 percent cure after 25 ± 13 treatments over 3.2 ± 1.7 months. Onfollow-up (median 18
months), only 3/81 (4 percent) had reulceration, which responded to THBO/LEL retreatment. Non-
responders had significantly lower ankle brachial indices (ABI) than patients whose ulcers were
healed (0.55 vs. 0.78, p < 0.01) and ultimately required amputation. Patient compliance wasfull
and no adverse events occurred. In conclusion, although the study was open and uncontrolled, an
81 percent healing ofDFU inpatients whopreviously didnot respond to a comprehensive treatment
program, constitutes an intriguingpreliminary result. Thus, THBO/LEL therapy may be a safe, sim-
ple, and inexpensive early adjunctive treatmentforpatients with chronic diabeticfoot ulcers. Our
findings shouldprompt its evaluation by large randomized controlled trials.
Chronic foot ulcers are a common
complication of long-standing diabetes,
affecting up to 20 percent of patients.
Their treatment is difficult, prolonged, and
often unsuccessful, and the patients are
prone to serious complications. Systemic
hyperbaric oxygen (HBO') therapy is used
as an adjunctive method to treat various
difficult wounds including diabetic foot
ulcers (DFU), even though its effective-
ness is still controversial [1]. A recent ran-
domized study showed that the addition of
systemic HBO treatment compared to con-
ventional treatment in diabetic patients
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with severe foot ulcers, decreased the need
for major amputation by almost four-fold
(relative risk 0.26) [2]. However, avail-
ability and cost somewhat limit the useful-
ness of this treatment modality. Interest-
ingly, topical HBO (THBO) treatment for
DFU and various chronic ulcers also
showed promising results in a few uncon-
trolled studies [3-5] but was largely aban-
doned following a prospective controlled
study which failed to demonstrate any
benefit. This study was too short, howev-
er, for meaningful conclusions and lasted
only 14 days [6].
The technology of low energy laser
(LEL) was introduced into clinical medi-
cine more than three decades ago but has
not received much attention. Nevertheless,
LEL has a stimulating effect on cell mito-
sis [7], keratinocyte migration and prolif-
eration [8, 9], and on cytokine production
[10, 11] and may lead to increased dermal
angiogenesis [12]. Animal experiments
have suggested an enhancing effect of
LEL on wound healing, and this was sup-
ported by a few preliminary clinical stud-
ies [13-15]. Investigations using both
THBO and LEL were not previously
reported to our knowledge, yet a synergis-
tic effect of combined therapy is possible
and our preliminary results were encour-
aging [16]. In this study we report our
experience with a combination of THBO
and LEL in the treatment of chronic dia-
betic foot ulcers when conventional treat-
ment failed.
PATIENTS AND METHODS
Since 1995, diabetic patients who had
chronic foot ulcers were referred to us by
general practitioners or by other clinics
(Vascular Surgery, diabetes) of the hospi-
tal. A complete history, physical examina-
tion, and appropriate blood tests were
obtained, as well as foot X-ray and ankle
blood pressure determination to calculate
ratio of ankle to brachial pressures (ABI).
All patients underwent a neurologic exam.
Biopsies and cultures were obtained as
needed but not routinely, and plethysmog-
raphy to assess venous flow was also per-
formed when clinically indicated. Conven-
tional treatment was administered by our
group, which included infectious diseases,
endocrinology, vascular surgery, and
orthopedic consultants. We aimed at opti-
mal diabetes and risk factor control and
administered recommendations for non-
weight bearing and special shoes, repeated
debridement and local treatment of the
ulcers, and prolonged use of broad spec-
trum antibiotics [17]. Therapies did not
include compression, Regranex (PDGF) or
recombinant skin. The patients were fre-
quently seen, mostly on an out-patient
basis. In addition, the team was easily
accessible to the patients, who could make
an appointment and be examined within a
short time. The first 100 consecutive
patients without gangrene whose ulcers
remained refractory to at least 14 weeks
(median 17 weeks) ofcomprehensive con-
ventional treatment by the team were
referred for THBO and LEL therapy and
are the subject of this study (see under
Results). THBO was administered by
pumping 100 percent humidified oxygen
into a hyperbaric chamber made ofa 100 x
60 cm disposable polyethylene bag placed
over the leg and sealed above the knee by
an elastic bandage (150 min x 2 to 3/week,
up to 1.04 atm). The same apparatus was
used for ambulatory treatment with a reg-
ular oxygen concentrator as an oxygen
source. Helium-neon LEL irradiation was
administered concurrently using a Uni-
laser Scan 60 (Elettronica, Pagany, Italy).
The unit has an automatic scanner and pro-
vided low sources of laser (wavelength
and power of 632.8 nm/5mW and 904
nm/60W, for He-Ne and infrared laser,
respectively). During each treatment a
dose of 4 J/cm2 was irradiated to the sur-
face of the ulcer, for 20 minutes. Over the
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continued as necessary. Patients were
monitored at least once every two weeks
and the appearance of the ulcer recorded
by the same observer. The primary end
point was ulcer healing, defined as com-
plete closure ofthe ulcer with normal skin
or scar formation. Following ulcer heal-
ing, patient follow-up was continued at a
lower frequency but at least once every
three months.
RESULTS
Over the period of the study, 347
patients with diabetic foot ulcers were
referred to us. In 233 patients, cure of the
ulcer was achieved by conventional thera-
py (67 percent), and 14 were lost to follow
up. The remaining first 100 patients whose
ulcers did not heal with prolonged estab-
lished therapy over 4.5 ± 1.2 months
(median 17 weeks, range 14 to 24 weeks)
are the subject ofthe present study. All 100
patients had longstanding type 2 diabetes
(median 11 years). Their ages were 64 +
10 years (mean ± SD), 51 percent were
males. Most patients' diabetes was treated
with oral agents, and only a small minori-
ty were treated with insulin. Diabetes was
poorly controlled in most patients at pre-
sentation (Hb A1C > 7.5 percent) and also
notable was a high frequency of other
microvascular complications such as dia-
betic retinopathy and nephropathy. All
patients (100 percent) had diabetic periph-
eral neuropathy on presentation. The foot
ulcers were present for 7 ± 5 months
(range 2 to 17 months) before referral.
Most patients were treated with both
THBO and LEL therapy, and the mean
duration of treatment was 3.2 ± 1.7
months. The treatment characteristics and
results are given in Table 1. Eighty-one
patients (81 percent) were cured. On a
median follow-up of 18 months (range 12
to 39 months), reulceration occurred in
only 4 percent (3/81) and early retreatment
with THBO/LELled again to ulcer healing
in all cases. Amputations were limited to
those patients who failed treatment
(19/19), and these patients had lower ABI
than those who responded to THBO/LEL
treatment (0.55 ± 0.14 vs. 0.78 ± 0.18, p <
0.01), but no other significant differences
were found (not shown). No adverse reac-
tions were noted and notably, no patient
was lost to follow up. Patient compliance
was maximal (100 percent). Part of this
adherence can no doubt be attributed to
patient satisfaction. Patients often
Table 1. Treatment of 100 diabetic patients with chronic foot ulcers who failed con-
ventional treatment bytopical hyperbaric oxygen (THBO) and low energy laser (LEL)
therapy.
Ulcer duration before referral (months) 7 + 5
Conventional treatment duration (months) 4.5 + 1.2
THBO & LEL treatment:
Duration (months) 3.2 + 1.7
Number of treatments 25 + 13
Treatment group and results (cured/total in group):
a. In hospital THBO & LEL 53/64 (83%)
b. In hospital THBO & LEL followed by THBO at home 21/25 (84%)
c. THBO alone, at home 7/11 (64%)a
Total curedb 81/100 (81%)
Recurrent ulcerationc 3/81 (4%)
a Nineteen patients failed and ultimately required amputation
b Differences between a and b and between a + b and c are not statistically significant.
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expressed their satisfaction with the pro-
gram, enthusiasm with the results (not
quantitated), and stressed their wish to
remain on the study and continue THBO
treatment.
DISCUSSION
Diabetic foot ulcers are notoriously
prone to complications and resistant to
therapy [17]. Even with "best" conven-
tional treatment which includes improved
glycemic control, decreased weight bear-
ing, local treatment of the ulcers and sys-
temic antibiotics, many ulcers remain
unhealed. Our combined conventional
therapy achieved primary healing in 67
percent ofthe patients only. This is consis-
tent with the results ofother centers which
reported success in 182/281 Swedish
patients (65 percent) [18] and in 55 to 63
percent of the patients in two additional
recent series [19, 20]. This result, there-
fore, supports the contention that the non-
responding patients referred for
THBO/LELtherapy were truly resistant or
refractory to prolonged "conventional"
treatment.
Our approach, of adding THBO and
LEL therapy to the multi-disciplinary con-
ventional modalities is based on previous
biological and early clinical observations
[3-15]. It resulted in afurther 80percent of
the patients with chronic diabetic foot
ulcers being cured. The results are even
more striking considering the fact that
prior prolonged conventional therapy for
about four months failed in these patients.
Nevertheless, subsequently, about 12
weeks only of adjunctive THBO/LEL
therapy were sufficient to obtain ulcercure
in most ofthe patients (Table 1). This sug-
gests that the introduction of adjunctive
THBO/LEL therapy at an early, initial
stage of DFU treatment, might be benefi-
cial. Using this approach for both naive
and treatment-resistant DFU might also be
cost effective, since both modalities do not
require expensive equipment orpersonnel.
Furthermore, THBO can be continued at
the patient's home, apparently with no sig-
nificant loss of efficacy (Table 1). One
rationale oftreatment ofdiabetic footulcer
with THBO is to use the lethal effect of
oxygen on the anaerobic bacteria present
in the diabetic ulcer. Indeed we observed
that after a few treatments the foul odor of
anaerobic bacteria disappeared from the
ulcers. Although the identification of
microbiological isolates from foot ulcers
was not routinely attempted in this study,
data from other studies show that DFU
yield mixed cultures of microorganisms
[8, 21]. Staphylococci (both Staphylococ-
cusaureus andcoagulase-negative Staphy-
lococcus) predominate, but other Gram-
positive, Gram-negative and anaerobic
bacteria are often found. Infections are
usually polymicrobial and curettage ofthe
base of foot ulcers or deep tissue cultures
are most reliable for identifying true
pathogens [22, 23] as opposed to simple
cultures of the foot ulcer. We used pro-
longed courses of broad spectrum beta-
lactam antibiotics or a combination of
antibiotics active against facultatively aer-
obic cocci and bacilli as well as anaerobes,
administered early as part of the standard
therapy. Nevertheless a sizeable propor-
tion (one third) of the patients' ulcers
remained refractory, but later showed a
response rate of about 80 percent to
THBO/LEL treatments.
HBO, even at low pressures as used
by us, has an additional stimulatory effect
on wound healing and its combination
with LEL may have an additive effect: in
four patients who developed a new ulcer
while on ambulatory THBO therapy,
immediate LEL application cured their
lesion very quickly, again suggesting that
early THBO/LEL intervention might fur-
ther improve the results. This is supported
by a recent randomized controlled trial of
LEL vs. sham irradiation in 30 patients
with DFU or gangrene, which found aLandau and Schattner: Hyperbaric oxygen for diabetic foot ulcers 99
significant rise in skin temperature in the
LEL group, reflecting improved skin
microcirculation [24]. This finding may
underlie the remarkably low rate of ulcer
recurrence in our series, as opposed to a
reported recurrence rate of more than a
third of patients within one year [25].
This is an unexpected observation which
merits further confirmation.
Several limitations of our study
should be noted. Our study was open,
unblinded, and our patients served as their
own controls in the period of"convention-
al" therapy. This is problematic and open
to criticism that the observed high rate of
ulcer cure is merely the result of further
prolonging conventional treatment. How-
ever, after 4.5 ± 1.2 months, we felt that
our patients' foot ulcers were truly refrac-
tory to established treatments and this is
line with historical controls [18-20]. It is
also not entirely clear which of the two
treatments, or their combined use, was the
effective modality. The differences in ther-
apeutic effects between the two groups
(THBO/LEL vs. THBO alone) were
insignificant (Table 1). On the other hand,
the high safety profile of both treatments
suggest that until further data are avail-
able, concurrent treatment should be
attempted whenever possible.
We conclude that in conjunction with
standard treatments, the added application
of THBO/LEL may have a true beneficial
effect on the natural history of chronic
therapy-resistant diabetic foot ulcers. This
is also reflected in the low prevalence of
reulceration. THBO/LEL treatment is sim-
ple, inexpensive, and can easily be adopt-
ed to primary care settings. Thus, our main
conclusion is that these preliminary results
should resurrect interest in adjunctive
THBO/LEL therapy for chronic foot
ulcers in diabetic patients, and should lead
to large-scale randomized controlled trials
in the future.
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